KALA BIO, Inc. $KALA Stock Holdings Raised by ADAR1 Capital Management LLC

Key Points

• ADAR1 Capital Management LLC increased its stake in KALA BIO by 35.7% during Q1, acquiring an additional 78,582 shares and now holds approximately 4.63% of the company, worth around $1.7 million.
• KALA BIO shares have seen a remarkable 400% increase in the past month, prompting interest from multiple institutional investors, including OCONNOR A Distinct Business Unit of UBS and AIGH Capital Management.
• Despite a recent uptick in stock prices, KALA BIO's recent quarterly earnings reported a loss of ($1.71) per share, which slightly exceeded consensus estimates, as analysts anticipate continued losses averaging -10.84 EPS for the current year.

ADAR1 Capital Management LLC raised its position in KALA BIO, Inc. (NASDAQ:KALA - Free Report) by 35.7% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 298,955 shares of the company's stock after purchasing an additional 78,582 shares during the period. ADAR1 Capital Management LLC owned about 4.63% of KALA BIO worth $1,713,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Readystate Asset Management LP acquired a new stake in KALA BIO in the 1st quarter valued at about $243,000. AIGH Capital Management LLC lifted its stake in KALA BIO by 61.9% in the 1st quarter. AIGH Capital Management LLC now owns 196,350 shares of the company's stock valued at $1,125,000 after buying an additional 75,048 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of KALA BIO by 10.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 178,934 shares of the company's stock worth $1,242,000 after buying an additional 16,271 shares in the last quarter. Institutional investors and hedge funds own 24.61% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on KALA. HC Wainwright reduced their target price on KALA BIO from $15.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, May 23rd. Wall Street Zen lowered shares of KALA BIO from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Oppenheimer restated an "outperform" rating and issued a $15.00 target price on shares of KALA BIO in a report on Monday, June 2nd. Lifesci Capital raised shares of KALA BIO to a "strong-buy" rating in a research report on Wednesday. Finally, LADENBURG THALM/SH SH assumed coverage on shares of KALA BIO in a research note on Friday, July 11th. They set a "buy" rating and a $12.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $13.00.

KALA BIO Trading Up 0.1%

Shares of KALA stock traded up $0.02 during mid-day trading on Friday, reaching $14.55. The company's stock had a trading volume of 367,177 shares, compared to its average volume of 187,084. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 3.19. The firm has a market capitalization of $102.14 million, a PE ratio of -2.14 and a beta of -1.81. The company's 50 day simple moving average is $7.78 and its 200-day simple moving average is $5.80. KALA BIO, Inc. has a 12-month low of $2.92 and a 12-month high of $15.80.

KALA BIO (NASDAQ:KALA - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported ($1.71) EPS for the quarter, beating the consensus estimate of ($1.82) by $0.11. On average, research analysts predict that KALA BIO, Inc. will post -10.84 EPS for the current fiscal year.

Insider Activity at KALA BIO

In related news, Director Mark T. Iwicki sold 13,227 shares of the stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $4.01, for a total value of $53,040.27. Following the completion of the transaction, the director owned 258,433 shares of the company's stock, valued at approximately $1,036,316.33. This represents a 4.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold a total of 30,678 shares of company stock valued at $123,019 in the last 90 days. Insiders own 8.32% of the company's stock.

KALA BIO Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.